ImmunityBio Reports Significant Revenue Growth and Operational Developments for Q2 2025

ImmunityBio, Inc. reported a net product revenue of $26.42 million for the three months ended June 30, 2025, a significant increase from the $0.99 million reported for the same period in 2024, primarily driven by sales of ANKTIVA. Total revenue for the quarter was $26.43 million, compared to $1.05 million in the prior year. Operating costs and expenses decreased slightly to $97.71 million from $100.38 million in 2024. The loss from operations was reduced to $71.29 million from $99.33 million year-over-year. Net loss attributable to ImmunityBio common stockholders was $92.56 million, or $0.10 per share, compared to $134.56 million, or $0.20 per share, in the prior year.

For the six months ended June 30, 2025, ImmunityBio reported net product revenue of $42.93 million, a substantial increase from the $0.99 million reported for the same period in 2024. Total revenue was $42.94 million, compared to $1.09 million in the prior year. Research and development expenses decreased slightly to $103.47 million from $104.48 million in 2024, while selling, general, and administrative expenses decreased to $74.99 million from $91.14 million. The loss from operations was reduced to $135.71 million from $194.53 million year-over-year. Net loss attributable to ImmunityBio common stockholders was $222.20 million, or $0.26 per share, compared to $268.67 million, or $0.40 per share, in the prior year.

Key operational developments included the MHRA granting marketing authorization in the UK for ANKTIVA in combination with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors, marking the first marketing approval outside the U.S. for ANKTIVA. The company also launched ResQ201A, a randomized controlled trial in the U.S., evaluating ANKTIVA in combination with tislelizumab for patients with second-line lung cancer progressing on checkpoint inhibitors. Full enrollment was reached in the randomized NCI cancer prevention clinical trial using ANKTIVA in combination with adenovirus vaccine in 186 patients with Lynch Syndrome.

As of June 30, 2025, ImmunityBio had cash and cash equivalents, and marketable securities totaling $153.7 million. The company believes that its existing cash and cash equivalents, investments in marketable securities, sales of ANKTIVA, potential capital to be raised through equity offerings, and potential ability to borrow from affiliated entities will be sufficient to fund its operations through at least the next 12 months. Subsequent to the end of the quarter, on July 24, 2025, ImmunityBio entered into a securities purchase agreement with institutional investors for the purchase and sale of common stock and warrants, generating net proceeds of approximately $75.3 million.